Pascale C.
- Country
- France
- Department
- Medical oncolgy
Research Overview
Data & Insights
Has run more than one trial at 0 of 18 partner sites.
Specializations
HER2‑Positive Breast Cancer Therapeutics
Focus on targeted strategies for HER2‑positive disease, including de‑escalation after prolonged response and central nervous system involvement.
- HER2‑positive metastatic breast cancer treatment de‑escalation
- Intrathecal therapy for leptomeningeal metastases
- Trastuzumab‑deruxtecan combined with chemotherapy
- Neoadjuvant HER2‑targeted regimens and residual disease assessment
Investigations emphasize long‑term disease control and biomarker‑driven therapy adjustments.
Advanced Lung Cancer and Neuroendocrine Tumors
Addresses non‑small cell lung cancer, large‑cell neuroendocrine carcinoma, and KRAS‑mutated subsets with immunotherapy and targeted agents.
- Non‑small cell lung cancer KRAS‑G12C targeted therapy
- Large‑cell neuroendocrine carcinoma first‑line chemo‑immunotherapy
- Immunotherapy combinations in advanced lung cancer
- Neuroendocrine gastrointestinal tumors with peptide‑receptor radionuclide therapy
Efforts integrate molecular profiling to refine therapeutic selection.
Gastrointestinal Oncology
Covers gastric, gastro‑esophageal junction, colorectal, and cholangiocarcinoma, focusing on HER2, claudin‑18.2, and MSI biomarkers.
- HER2‑positive gastric and GEJ cancer treatment strategies
- Claudin‑18.2 targeted therapy in gastric malignancies
- Metastatic colorectal cancer with anti‑angiogenic agents
- Intrahepatic cholangiocarcinoma adjuvant and metastatic approaches
Clinical work prioritizes biomarker‑guided regimens and combination modalities.
Prostate Cancer Precision Therapies
Explores castration‑resistant and hormone‑sensitive prostate cancer using PSMA‑targeted radioligand therapy and intensified local treatment.
- PSMA‑positive metastatic castration‑resistant prostate cancer radioligand therapy
- High‑risk localized prostate cancer with stereotactic radiotherapy
- Hormone‑sensitive prostate cancer combined with PSMA‑directed agents
- Post‑irradiation prostate bed relapse management
Research integrates advanced imaging to select candidates for targeted radionuclide treatment.
Supportive Oncology and Symptom Management
Targets cancer‑associated cachexia, chemotherapy‑induced peripheral neuropathy, and vasomotor symptoms in hormone‑responsive breast cancer.
- Cancer‑associated cachexia therapeutic interventions
- Chemotherapy‑induced peripheral neuropathy pain control
- Vasomotor symptoms from adjuvant endocrine therapy
- Brain radionecrosis management with anti‑angiogenic agents
Aim is to improve quality of life alongside disease‑directed treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.